DIA names new managing director for China
This article was originally published in Scrip
Life Sciences association, the DIA, has named Dr Haijun Dong managing director in China. Dr Dong was previously chief executive officer of Lilly China Research and Development, a subsidiary of Eli Lilly, and was president and CEO of IMPACT Therapeutics. Furthermore, Dr Dong has in the past worked for Swiss big pharma Roche in China and the US. He succeeds Dr Jane Cai, who is retiring from the role of MD for DIA China.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.